POZ Community Forums

Meds, Mind, Body & Benefits => Research News & Studies => Topic started by: MitchMiller on September 17, 2021, 09:42:55 pm

Title: EBT-101
Post by: MitchMiller on September 17, 2021, 09:42:55 pm
After reading about it for a few years, CRISPR is about to be trialed in humans to excise HIV from cells.  The hope is that enough virus (including latent virus) can be removed from the body to accomplish a functional cure.  It has already worked on primates that have SIV. 

https://www.phillymag.com/healthcare-news/2021/03/05/excision-biotherapeutics-temple-hiv-clinical-trial/ (https://www.phillymag.com/healthcare-news/2021/03/05/excision-biotherapeutics-temple-hiv-clinical-trial/)
Title: Re: EBT-101
Post by: em on November 04, 2021, 04:35:11 pm
new article on this https://www.popbuzz.com/life/news/hiv-cure-excision-biotherapeutics-ebt-101-trial/ this one is from facebook HIV long term survivors.
 https://www.gaytimes.co.uk/life/functional-cure-for-hiv-approved-for-human-trials/?fbclid=IwAR2HorT37AICI0j6Zyj_lPXee4Z7A8RVEDsrQiDVDntticuIF25PXKbjH6A

human trials ,    any thoughts
Title: Re: EBT-101
Post by: Jim Allen on November 05, 2021, 12:04:32 pm
Quote
human trials ,    any thoughts

The same thoughts I had in 2016 about Dr. Khalili work with CRISPR when they cured a mouse and in 2020 on the primate. Scientifically interesting but no other thoughts at such an early stage.


Title: Re: EBT-101
Post by: CircularNatural on November 05, 2021, 04:09:10 pm
It's so interesting to follow this kind of novel treatments... one can only be hopeful  ;D :D :)
Title: Re: EBT-101
Post by: Da2020 on January 23, 2022, 05:30:43 pm
They have posted it on clinicaltrails.gov in December and recently updated the trail start date as Jan 2022. If only they would start the trail. It is a very interesting approach and trail. They want to start ATI within 3 months which is definitely very interesting
Title: Re: EBT-101
Post by: em on January 24, 2022, 07:14:59 am
trial information

https://clinicaltrials.gov/ct2/show/NCT05144386
Title: Re: EBT-101
Post by: Da2020 on February 20, 2022, 08:19:03 pm
They have started the trail in St.Louis, MO
Title: Re: EBT-101
Post by: Da2020 on May 22, 2022, 04:39:53 pm
They have presented a poster demonstrating, no off target cuts . At least we know its not going to create zombies :)
Title: Re: EBT-101
Post by: geobee on May 31, 2022, 12:46:10 am
Another breathless "milestone" -- demonstrated "efficacy" against HIV.

https://www.americangene.com/news-releases/agt-hiv-blood-markers-of-efficacy-more-patients/
Title: Re: EBT-101
Post by: Da2020 on May 31, 2022, 02:49:06 pm
Another breathless "milestone" -- demonstrated "efficacy" against HIV.

https://www.americangene.com/news-releases/agt-hiv-blood-markers-of-efficacy-more-patients/

They have reaped this news in February, there actually is a separate thread tracking them
Title: Re: EBT-101
Post by: Cosmicdancer on September 18, 2022, 11:03:09 am
Excision BioTherapeutics Doses First Participant in EBT-101 Phase 1/2 Trial Evaluating EBT-101 as a Potential Cure for HIV

* EBT-101 is an in vivo CRISPR-based therapeutic designed to remove HIV proviral DNA from affected cell reservoirs

* First-in-human study will evaluate the safety and efficacy of EBT-101 in participants who chronically suppress HIV with daily antiretroviral therapy

* EBT-101 has been well tolerated to-date and the trial is proceeding as planned

SAN FRANCISCO, Sept. 15, 2022 (GLOBE NEWSWIRE) -- Excision BioTherapeutics, Inc., a clinical-stage biotechnology company developing CRISPR-based therapies intended to cure viral infectious diseases, today announced that the first participant has been dosed in the Phase 1/2 clinical trial of EBT-101 for human immunodeficiency virus type 1 (HIV-1). The participant was dosed in July 2022, with initial findings indicating EBT-101 has been well tolerated to-date. The participant continues to be monitored for safety and is expected to qualify for analytical treatment interruption (ATI) of their background anti-retroviral therapy (ART) in an evaluation of a potential cure.

“Dosing the first participant with EBT-101 is a landmark event that solidifies Excision’s position as a pioneer in gene editing,” said Daniel Dornbusch, Chief Executive Officer of Excision. “It is the first time a CRISPR-based therapy targeting an infectious disease has been administered to a patient and is expected to enable the first ever clinical assessment of a multiplexed, in vivo gene editing approach. We were able to reach this watershed moment thanks to years of innovative work by leading scientists and physicians, to whom we are immensely grateful. With this achievement, Excision has taken a major step forward in developing a one-time treatment that could transform the HIV pandemic by freeing affected people from life-long disease management and the stigma of disease."

https://www.tmcnet.com//usubmit/2022/09/15/9674271.htm